Galena Biopharma, Inc. (NASDAQ:GALE)

CAPS Rating: 1 out of 5

Results 1 - 9 of 9

Recs

0
Member Avatar StarWitchDoctor (99.38) Submitted: 7/28/2015 4:11:17 PM : Underperform Start Price: $4.22 GALE Score: +73.16

cow me down

Recs

1
Member Avatar blackswanexposur (23.22) Submitted: 6/17/2015 4:43:10 PM : Outperform Start Price: $1.85 GALE Score: -8.10

Risky biotech pharma play. Well documented risks include 1) pending shareholder class-action lawsuit, and 2) diminishing cash reserves available to fund approximately one year of operations. Motion to dismiss class-action suit is currently under review by a judge in Oregon, though timeline of ruling is unknown.

Current medications on the market have struggled to gain market share and have not provided anticipated revenue to help fund operations. The real value in this stock, however, is the developing pipeline of cancer immunotherapies led by NeuVax, which is in Phase III trials. NeuVax is being developed to prevent recurrence of specific types of breast cancer. Additional drugs are in Phase II trials.

GALE will likely need a partnership or sell additional shares in the next year to fund ongoing trials, though the current share price does represent a distressed valuation. Potential collaborations, positive interim data for NeuVax, or ultimately FDA approval of NeuVax should result in significant movement of share price. High risk-high reward.

Recs

0
Member Avatar drugtrader (95.08) Submitted: 3/25/2015 12:31:39 AM : Outperform Start Price: $1.49 GALE Score: +13.28

2 thumbs up from zzporte! I wasn't sure which way to go thanks.

Recs

1
Member Avatar ruinas (58.18) Submitted: 12/27/2014 3:50:21 PM : Underperform Start Price: $1.53 GALE Score: -9.89

Markets overbought - correction due

Recs

0
Member Avatar bargain123 (27.70) Submitted: 12/26/2014 5:46:04 PM : Outperform Start Price: $1.53 GALE Score: +9.89

Technicals look good, product matured, this company will either make money on its own or been bought by Big Guy in this space

Recs

0
Member Avatar DougD720 (< 20) Submitted: 7/17/2014 11:05:35 AM : Outperform Start Price: $2.65 GALE Score: -42.60

Neuvax, highly undervalued due to scandal, still solid company with an excellent pipeline.

Recs

0
Member Avatar herbertslojewski (64.96) Submitted: 7/7/2014 3:56:58 PM : Outperform Start Price: $2.94 GALE Score: -49.32

Great new anti-cancer developments.

Recs

0
Member Avatar manirg (95.63) Submitted: 3/11/2014 9:48:12 AM : Outperform Start Price: $3.37 GALE Score: -61.80

highly undervalued, huge potential, has 2 drugs approved

Recs

0
Member Avatar jgvega (< 20) Submitted: 2/23/2014 3:58:40 PM : Outperform Start Price: $3.92 GALE Score: -71.01

Great chances of being revenue positive towards the end of the year thanks to drug Abstral. Huge market potential for breast cancer drug NueVax (if passed by FDA. it has great chances). Positive ratings from many analysts. Oh, and it’s undervalued due to recently ended bear raid. All and all, great stock and price with multi bagger potential for 2014. check it out.

Results 1 - 9 of 9

Featured Broker Partners


Advertisement